As nanotechology burrows into an increasing number of medical technologies, new developments in nanoparticles point to the ways that treatments can today be nanotechnologically targeted. In one case, would-be end effectors on microrobots are aimed at clearing up cases of bacterial pneumonia. In another, a smart-targeting system may decrease clotting risks in dangerous cases of thrombosis.
Scientists from the University of California, San Diego, demonstrated antibiotic-filled nanoparticles that hitch a ride on microbots made of algae to deliver targeted therapeutics. Their paper was recently published in Nature Materials. As a proof of concept, the researchers administered antibiotic-laden microbots to mice infected with a potentially fatal variety of pneumonia (a strain that is common in human patients who are receiving mechanical ventilation in intensive-care settings). All infections in the treated mice cleared up within a week, while untreated mice died within three days.
The algae–nanoparticle hybrid microbots were effectively distributed to infected tissue through lung fluid and showed negligible toxicity. “Our goal is to do targeted drug delivery into more challenging parts of the body, like the lungs,” said bioengineering professor Liangfang Zhang in a press statement. “And we want to do it in a way that is safe, easy, biocompatible, and long lasting.”
A paralyzed man who hasn’t spoken in 15 years uses a brain-computer interface that decodes his intended speech, one word at a time.
“It is not enough to study brain connectivity with one single method, or even two,” says HBP Scientific Director and author of the Science article Katrin Amunts, who leads the Institute of Neuroscience and Medicine (INM-1) at Forschungszentrum Jülich and the C. & O. Vogt Institute of Brain Research at the University Hospital Düsseldorf. “The connectome is nested at multiple levels. To understand its structure, we need to look at several spatial scales at once by combining different experimental methods in a multi-scale approach and by integrating the obtained data into multilevel atlases such as the Julich Brain Atlas that we have developed.”
Markus Axer from Forschungszentrum Jülich and the Physics Department of the University of Wuppertal, who is the first author of the Science article, has together with his team at INM-1 developed a unique method called 3D Polarised Light Imaging (3D-PLI) to visualise nerve fibres at microscopic resolution. They trace the three-dimensional courses of fibres across serial brain sections with the aim of developing a 3D fibre atlas of the entire human brain.
Together with other HBP researchers from Neurospin in France and the University of Florence in Italy, Axer and his team have recently imaged the same tissue block from a human hippocampus using several different methods: anatomical and diffusion magnetic resonance imaging (aMRI and dMRI), two-photon fluorescence microscopy (TPFM) and 3D-PLI, respectively.
A novel brain-computer interface developed by a New York-based company called Synchron was just used to help a paralyzed patient send messages using their Apple device for the very first time. It’s a massive step up in an industry that has increasingly reported progress, which suggests that interfacing our minds with consumer devices could happen a lot sooner than some of us bargained for.
Brain-computer devices eavesdrop on brainwaves and convert these into commands. More or less the same neural signals that healthy people use to instruct their muscle fibers to twitch and enact a movement like walking or grasping an object can be used to command a robotic arm or move a cursor on a computer screen. It really is a phenomenal and game-changing piece of technology, with obvious benefits for those who are completely paralyzed and have few if any means of communicating with the outside world.
This type of technology is not exactly new. Scientists have been experimenting with brain-computer interfaces for decades, but it’s been in the last couple of years or so that we’ve actually come to see tremendous progress. Even Elon Musk has jumped on this bandwagon, founding a company called Neuralink with the ultimate goal of developing technology that allows people to transmit and receive information between their brain and a computer wirelessly — essentially connecting the human mind to devices. The idea is for anyone to be able to use this technology, even normal, healthy people, who want to augment their abilities by interfacing with machines. In 2021, Neuralink released a video of a monkey with an implanted Neuralink device playing pong, and the company wants to start clinical trials with humans soon.
With inherited gene mutations from both parents, a woman in Spain is battling with 12 tumors in her body.
As stated by the Spanish National Cancer Research Centre (CNIO), the woman first developed a tumor when still a baby and other tumors followed it within five years. 36 year-old-patient has developed twelve tumors, at least five of them malignant in her life. Each one has been of a unique kind and has affected a different area of the body.
“We still don’t understand how this individual could have formed during the embryonic stage, nor could have overcome all these pathologies,” says Marcos Malumbres, director of the Cell Division and Cancer Group at the Spanish National Cancer Research Centre (CNIO).
For the last few decades, battery research has largely focused on rechargeable lithium-ion batteries, which are used in everything from electric cars to portable electronics and have improved dramatically in terms of affordability and capacity. But nonrechargeable batteries have seen little improvement during that time, despite their crucial role in many important uses such as implantable medical devices like pacemakers.
Now, researchers at MIT have come up with a way to improve the energy density of these nonrechargeable, or “primary,” batteries. They say it could enable up to a 50% increase in useful lifetime, or a corresponding decrease in size and weight for a given amount of power or energy capacity, while also improving safety, with little or no increase in cost.
The new findings, which involve substituting the conventionally inactive battery electrolyte with a material that is active for energy delivery, are reported today in the journal Proceedings of the National Academy of Sciences, in a paper by MIT Kavanaugh Postdoctoral Fellow Haining Gao, graduate student Alejandro Sevilla, associate professor of mechanical engineering Betar Gallant, and four others at MIT and Caltech.
New foundation aims for scientific and rhetorical value – and to run the debug cycle for longevity research.
The Longevity Investors Conference is quickly turning into one of the highlights in the longevity calendar, and we were delighted to be able to interview some of the speakers in a few ‘backstage’ moments.
Held in the exclusive location of Gstaad in Switzerland, The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. Dr Aubrey de Grey was in Gstaad to address the conference on rejuvenation biotechnology as well as being part of a panel discussing where crypto meets longevity.
Visit Longevity. Technology — https://bit.ly/3PwtH8Y
Follow Longevity. Technology on:
Twitter — https://bit.ly/3AMIXuq.
Facebook — https://bit.ly/3z8H1v5
Instagram — https://bit.ly/3IDvVRX
Linkedin — https://bit.ly/3yIfDmf